Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brivoligide - Adynxx

Drug Profile

Brivoligide - Adynxx

Alternative Names: AYX-1; Brivoligide-sodium

Latest Information Update: 20 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adynxx
  • Class Analgesics; Oligonucleotides
  • Mechanism of Action Early growth response protein 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pain; Postoperative pain

Most Recent Events

  • 09 Jul 2020 Adynxx withdraws a phase II ADYX-005 trial for Postoperative pain in patients undergoing unilateral total knee arthroplasty or TKA prior to enrolment owing to delay in trial initiation due to COVID-19 pandemic in USA (NCT03797612)
  • 09 Jul 2020 Adynxx withdraws a phase II ADYX-006 trial for Postoperative pain in patients undergoing mastectomy with immediate tissue expander or implant placement prior to enrolment owing to delay in trial initiation due to COVID-19 pandemic in USA (NCT04104919)
  • 14 Nov 2019 Adynxx plans the phase II ADYX-005 trial for Postoperative pain in USA in participants undergoing unilateral total knee arthroplasty or TKA in the first quarter of 2020 (NCT03797612)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top